Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Merrimack Pharmaceuticals clinical trials
The registry lists 25 studies whose lead sponsor is Merrimack Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 18, 2018.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Merrimack Pharmaceuticals.
- Merrimack Pharmaceuticals25 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic CancerCompletedNCT02399137Phase 2
- Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentCompletedNCT01520389Phase 1
- A Study Evaluating MM-310 in Patients With Solid TumorsStatus unknownNCT03076372Phase 1
- Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibTerminatedNCT02538627Phase 1
- A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and StomachTerminatedNCT01774851Phase 2
- Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal CancerWithdrawnNCT02785068Phase 1/2
- MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsTerminatedNCT02213744Phase 2/3
- Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast CancerStatus unknownNCT01304797Phase 1
- Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid TumorsCompletedNCT01447225Phase 1
- A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersCompletedNCT01209195Phase 1
- A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersCompletedNCT01451632Phase 1
- Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentCompletedNCT00734305Phase 1
- A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00994123Phase 1/2
- A Phase 1 Study of MM-141 in Patients With Advanced Solid TumorsCompletedNCT01733004Phase 1
- Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic CancerCompletedNCT01494506Phase 3
- Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast CancerCompletedNCT01151046Phase 2
- A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian CancersCompletedNCT01447706Phase 2
- A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerCompletedNCT01421472Phase 2
- A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive CancerCompletedNCT01304784Phase 1
- A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive CancersCompletedNCT00911898Phase 1
- MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast CancerCompletedNCT01097460Phase 1
- Phase 2 Study of MM-093 to Treat Patients With UveitisCompletedNCT00444743Phase 2
- Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)CompletedNCT00105976Phase 2
- A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid ArthritisCompletedNCT00458146Phase 2
- Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque PsoriasisCompletedNCT00147329Phase 2